ethyl 2,4,6‐trimethylpyrimidine‐5‐carboxylate | 90905-54-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: ethyl 2,4,6‐trimethylpyrimidine‐5‐carboxylate
• 英文别名: 5-ethoxycarbonyl-2,4,6-trimethylpyrimidine；2,4,6-trimethyl-pyrimidine-5-carboxylic acid ethyl ester；2,4,6-Trimethyl-pyrimidin-5-carbonsaeure-aethylester；ethyl 2,4,6-trimethylpyrimidine-5-carboxylate
• CAS: 90905-54-7
• 化学式: C₁₀H₁₄N₂O₂
• 分子量: 194.233
• InChiKey: JLNRQWMYAYZEMG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  52.1
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  ethyl 2,4,6‐trimethylpyrimidine‐5‐carboxylate 在 肼 作用下， 生成 2,4,6-trimethyl-pyrimidine-5-carboxylic acid hydrazide
  参考文献：
  名称：

  合成氨基5-嘧啶及磺胺类化合物的对应物

  摘要：

  通过各种方法合成被烷基和烷氧基取代的5-氨基嘧啶。由它们制得的一些磺酰苯胺具有强烈而持久的化学治疗作用。

  DOI：

  10.1002/hlca.19580410635
• 作为产物：
  描述：

  二乙酰乙酸乙酯 在 sodium ethanolate 、 sodium 、 caesium carbonate 作用下， 以 乙醇 、 正己烷 、 乙腈 为溶剂， 反应 14.0h， 生成 ethyl 2,4,6‐trimethylpyrimidine‐5‐carboxylate
  参考文献：
  名称：

  用于光氧化还原催化的吖啶染料的合成与表征

  摘要：

  光氧化还原催化是一个快速发展的合成方法开发平台。吖啶盐作为光氧化还原催化剂的可持续选择的突出使用推动了基于这种支架的更强大和合成有用的版本的开发。然而，更复杂的合成、增加的成本和有限的商业可用性阻碍了更大的合成社区采用这些催化剂。通过利用黄嘌呤盐直接转化为相应的吖啶盐作为关键转化，我们提出了迄今为止报道的最具合成用途的吖啶盐的高效且可扩展的制备方法。这种不同的策略也使制备一套新型吖啶染料成为可能，

  DOI：

  10.1055/s-0037-1611744

文献信息

• Piperazine derivatives useful as CCR5 antagonists
  申请人：Schering Corporation

  公开号：US06391865B1

  公开（公告）日：2002-05-21

  The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R1 is hydrogen or alkyl; R2 is substituted phenyl, substituted heteroaryl, naphthyl, fluorenyl, diphenylmethyl or optionally substituted phenyl- or heteroaryl-alkyl; R3 is hydrogen, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, or optionally substituted phenyl, phenylalkyl, naphthyl, naphthylalkyl, heteroaryl or heteroarylalkyl; R4, R5 and R7 are hydrogen or alkyl; R6 is hydrogen, alkyl or alkenyl; for the treatment of HIV, solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis is disclosed, as well as novel compounds, pharmaceutical compositions comprising them, and the combination of CCR5 antagonists of the invention in combination with antiviral agents useful in the treatment of HIV or agents useful in the treatment of inflammatory diseases.

  公开了使用CCR5拮抗剂的公式，其中 R是可选择的取代苯基，吡啶基，噻吩基或萘基; R1是氢或烷基; R2是取代苯基，取代杂环基，萘基，芴基，二苯甲基或可选择的取代苯基或杂环基烷基; R3是氢，烷基，烷氧基烷基，环烷基，环烷基烷基，或可选择的取代苯基，苯基烷基，萘基，萘基烷基，杂环基或杂环基烷基; R4，R5和R7是氢或烷基; R6是氢，烷基或烯基; 用于治疗HIV，固体器官移植排斥，移植物宿主病，关节炎，类风湿关节炎，炎症性肠病，特应性皮炎，牛皮癣，哮喘，过敏或多发性硬化症的方法，以及包含它们的新化合物，包含它们的药物组合物，以及CCR5拮抗剂与抗HIV治疗中有用的抗病毒剂或与治疗炎症性疾病中有用的药物的组合。
• Herbicidal 5-pyrimidylcyclohexan-1,3-dione derivatives
  申请人：ICI Australia Limited

  公开号：US04659362A1

  公开（公告）日：1987-04-21

  The invention concerns novel compounds of the formula I ##STR1## wherein: X are selected from halogen, nitro, cyano, alkyl, substituted alkyl, hydroxy, alkoxy, substituted alkoxy, alkenyl, alkenyloxy, alkynyl, alkynyloxy, acyloxy, alkoxycarbonyl, alkylthio, alkylsulfinyl, alkylsulfonyl, sulfamoyl, substituted sulfamoyl, alkanoyloxy, benzyloxy, substituted benzyloxy, amino, substituted amino, and the groups formyl and alkanoyl and the oxime, imine and Schiff base derivatives thereof; R.sup.1 is selected from hydrogen, alkyl, alkenyl, alkynyl, substituted alkyl, alkylsulfonyl, arylsulfonyl, acyl and an inorganic or organic cation; R.sup.2 is selected from alkyl, substituted alkyl, alkenyl, haloalkenyl, alkynyl and haloalkynyl; R.sup.3 is selected from alkyl, fluoroalkyl, alkenyl, alkynyl, and phenyl; R.sup.4 is selected from hydrogen, halogen, alkyl, cyano and alkoxycarbonyl; and n is the integer 3. The compounds of the invention show herbicidal properties and plant growth regulating properties and in further embodiments the invention provides processes for the preparation of compounds of formula I, intermediates useful in the preparation of the compounds of formula I, compositions containing as active ingredient a compound of formula I, and herbicidal and plant growth regulating processes utilizing compounds of formula I.

  这项发明涉及公式I的新化合物： 其中：X从卤素、硝基、氰基、烷基、取代烷基、羟基、烷氧基、取代烷氧基、烯基、烯氧基、炔基、炔氧基、酰氧基、烷氧羰基、烷基硫醚、烷基砜基、烷基砜基、磺酰氨基、取代磺酰氨基、烷酰氧基、苄氧基、取代苄氧基、氨基、取代氨基、甲酰基和烷酰基以及其氧胺、亚胺和席夫碱衍生物中选择；R.sup.1从氢、烷基、烯基、炔基、取代烷基、烷基砜基、芳基砜基、酰基和无机或有机阳离子中选择；R.sup.2从烷基、取代烷基、烯基、卤代烯基、炔基和卤代炔基中选择；R.sup.3从烷基、氟烷基、烯基、炔基和苯基中选择；R.sup.4从氢、卤素、烷基、氰基和烷氧羰基中选择；n为整数3。 该发明的化合物具有除草性能和植物生长调节性能，此外，该发明还提供了制备公式I化合物的方法，用于制备公式I化合物的中间体，含有公式I化合物作为活性成分的组合物，以及利用公式I化合物的除草和植物生长调节过程。
• PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS
  申请人：Baroudy Bahige M.

  公开号：US20080188485A1

  公开（公告）日：2008-08-07

  The use of CCR 5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R 1 is hydrogen or alkyl; R 2 is substituted phenyl, substituted heteroaryl, naphthyl fluorenyl, diphenylmethyl or optionally substituted phenyl- or heteroarylalkyl; R 3 is hydrogen, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, or optionally substituted phenyl, phenylalkyl, naphthyl, naphthylalkyl, heteroaryl or heteroarylalkyl; R 4 , R 5 and R 7 are hydrogen or alkyl; R 6 is hydrogen, alkyl or alkenyl; for the treatment of HIV, solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis is disclosed, as well as novel compounds, pharmaceutical compositions comprising them, and the combination of CCR5 antagonists of the invention in combination with antiviral agents useful in the treatment of HIV or agents useful in the treatment of inflammatory diseases.

  本发明涉及CCR5拮抗剂的使用，其化学式为或其药学上可接受的盐，其中R是可选的取代苯基、吡啶基、噻吩基或萘基；R1是氢或烷基；R2是取代苯基、取代杂环芳基、萘基、芴基、二苯甲基或可选取代的苯基或杂环芳基烷基；R3是氢、烷基、烷氧基烷基、环烷基、环烷基烷基或可选取代的苯基、苯基烷基、萘基、萘基烷基、杂环芳基或杂环芳基烷基；R4、R5和R7是氢或烷基；R6是氢、烷基或烯基；用于治疗HIV、固体器官移植排斥、移植物抗宿主病、关节炎、类风湿性关节炎、炎症性肠病、特应性皮炎、牛皮癣、哮喘、过敏或多发性硬化症，以及新型化合物、包含它们的药物组合物，以及本发明的CCR5拮抗剂与用于治疗HIV或治疗炎症性疾病的抗病毒药物的组合。
• Herbicidal cyclohexane-1,3-dione derivatives
  申请人：ICI AUSTRALIA LIMITED

  公开号：EP0102823A2

  公开（公告）日：1984-03-14

  The invention concerns novel compounds of the formula I wherein: X are selected from halogen, nitro, cyano, alkyl, substituted alkyl, hydroxy, alkoxy, substituted alkoxy, alkenyl, alkenyloxy, alkynyl, alkynyloxy, acyloxy, alkoxycarbonyl, alkylthio, alkylsulfinyl, alkylsulfonyl, sulfamoyl, substituted sulfamoyl, alkanoyloxy, benzyloxy, substituted benzyloxy, amino, substituted amino, and the groups formyl and alkanoyl and the oxime, imine and Schiff base derivatives thereof; R' is selected from hydrogen, alkyl, alkenyl, alkynyl, substituted alkyl, alkylsulfonyl, arylsulfonyl, acyl and an inorganic or organic cation; R2 is selected from alkyl, substituted alkyl, alkenyl, haloalkenyl, alkynyl and haloalkynyl; R3 is selected from alkyl, fluoroalkyl, alkenyl, alkynyl, and phenyl; R4 is selected from hydrogen, halogen, alkyl, cyano and alkoxycarbonyl; and n is selected from the integers 1 to 3. The compounds of the invention show herbicidal properties and plant growth regulating properties and in further embodiments the invention provides processes for the preparation of compounds of formula 1, intermediates useful in the preparation of the compounds of formula I, compositions containing as active ingredient a compound of formula 1, and herbicidal and plant growth regulating processes utilizing compounds of formula I.

  本发明涉及式 I 的新型化合物 其中 X选自卤素、硝基、氰基、烷基、取代烷基、羟基、烷氧基、取代烷氧基、烯基、烯氧基、炔基、炔氧基、酰氧基、烷氧羰基、烷硫基、烷基亚磺酰基、烷基磺酰基、氨基磺酰基、取代氨基磺酰基、烷酰氧基、苄氧基、取代苄氧基、氨基、取代氨基、甲酰基和烷酰基及其肟、亚胺和席夫碱衍生物； R' 选自氢、烷基、烯基、炔基、取代烷基、烷基磺酰基、芳基磺酰基、酰基和无机或有机阳离子； R2 选自烷基、取代烷基、烯基、卤代烯基、炔基和卤代炔基； R3 选自烷基、氟烷基、烯基、炔基和苯基； R4 选自氢、卤素、烷基、氰基和烷氧羰基；以及 n 选自整数 1 至 3。 本发明的化合物具有除草特性和植物生长调节特性，在进一步的实施方案中，本发明提供了制备式 1 化合物的工艺、用于制备式 I 化合物的中间体、含有式 1 化合物作为活性成分的组合物，以及利用式 I 化合物的除草和植物生长调节工艺。
• Compounds and methods for the targeted degradation of androgen receptor
  申请人：Arvinas Operations, Inc.

  公开号：US11236051B2

  公开（公告）日：2022-02-01

  The present disclosure relates to bifunctional compounds, which find utility to degrade (and inhibit) Androgen Receptor. In particular, the present disclosure is directed to compounds, which contain on one end a cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds Androgen Receptor, such that Androgen Receptor is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of Androgen Receptor. The present disclosure exhibits a broad range of pharmacological activities associated with compounds according to the present disclosure, consistent with the degradation/inhibition of Androgen Receptor.

  本公开涉及双功能化合物，它们可用于降解（和抑制）雄激素受体。特别是，本公开涉及的化合物一端含有与 E3 泛素连接酶结合的脑龙配体，另一端含有与雄激素受体结合的分子，这样雄激素受体就被置于泛素连接酶附近，从而降解（和抑制）雄激素受体。本公开的化合物具有广泛的药理活性，与雄激素受体的降解/抑制作用相一致。